Introduction to thrombosis [email protected] Assistant Professor of Medicine...
-
Upload
brad-attridge -
Category
Documents
-
view
226 -
download
3
Transcript of Introduction to thrombosis [email protected] Assistant Professor of Medicine...
![Page 1: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/1.jpg)
Introduction to thrombosis
Assistant Professor of Medicine
Hematology/Oncology2014
![Page 2: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/2.jpg)
Objectives
1. Arterial Thrombosis: -Pathophysiology, Risk factors,
Symptoms and Signs, treatment 2. Venous Thrombosis:-Pathophysiology, Risk Factors,
Symptoms and Signs 3. Common anticoagulants 4. Hereditary and acquired
Hypercoagulable Disorders
![Page 3: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/3.jpg)
Summary of Hemostasis
Platelet plug forms
Stabilization byfibrin formation(clotting cascade)
Extension of clotlimited by:
Natural anticoagulants
Fibrinolysis
![Page 4: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/4.jpg)
Arteries versus Veins
Thick,muscular
Thin, pliable
High pressure
High oxygen
Low pressure
Low oxygen
Exception: pulmonary artery –O2 low
![Page 5: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/5.jpg)
Blood ClottingArterial Venous
Plateletsmore important
Blood clotting factorsmore important
![Page 6: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/6.jpg)
Pathogenesis
Atherosclerosis is a slow process that starts in childhood and results in occlusion of arterial blood vessels
Interruption of blood flow leads to hypoxia which causes ischemic damage of tissue, in the worst case tissue death (infarct)
Ischemia causes pain and malfunction of tissue/organ ( angina/Myocardial infarct, arrhythmias in the heart)
![Page 7: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/7.jpg)
Risk factors for arterial thrombosis
Smoking HTN cholesterol diabetes Homocysteine ? obesity sedentary life style Advanced age Family History Inflammation
Endothelial dysfunction
Fatty streak
Soft plaque
Hard plaque
Plaque rupture
Thrombosis/Occlusion
![Page 8: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/8.jpg)
Arterial Thrombosis-Clinical manifestations
1. Myocardial Infarction (Heart Attack)
-chest/arm pain pain, SOB, collapse, stomach pain2. Cerebrovascular accident CVA (Stroke)-dizziness, slurred speech, facial droop, one sided arm/leg weakness 3. Peripheral Vascular Disease (PVD),
chronic versus acute-sudden onset of severe pain, palor, cold skin ( No pulse palpable)
![Page 9: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/9.jpg)
Treatment of arterial thrombosis Acute: Anticoagulation with heparin
plus thrombolytic (tPA, urokinase, streptokinase)=“clot busters”
Long-term for primary or secondary prevention: antiplatelet therapy with ASA( acetylic salicylic acid=aspirin)
After Stent placement: Clopidogrel (Plavix) and ASA
No role for warfarin Risk factor modification important
![Page 10: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/10.jpg)
Objectives
1. Arterial Thrombosis: -Pathophysiology, Risk factors,
Symptoms and Signs, treatment 2. Venous Thrombosis:-Pathophysiology, Risk Factors,
Symptoms and Signs 3. Common anticoagulants 4. Hereditary and acquired
Hypercoagulable Disorders
![Page 11: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/11.jpg)
Case #1
24 y/o female AF cadet notices DOE over the course of 1 month
Can’t finish 2 hour hiking exercise, sent to local ED
CT Chest with PE protocol shows:
![Page 12: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/12.jpg)
![Page 13: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/13.jpg)
Case #2
A 63 y/o male develops new Right sided bulky Lymph adenopathy, night sweats and weight loss.
He is diagnosed with Diffuse large B-cell lymphoma and will require Chemotherapy
He undergoes placement of a PICC line R arm
3 days later he returns with a swollen, painful Right arm that is warm and has a slightly dusky discoloration.
US Doppler shows a thrombus in the axillary vein
![Page 14: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/14.jpg)
Case #3
A 76 y/o woman presents to the ER with a 2 day history of LE swelling. She also feels slightly SOB and has had hemoptysis on one occasion this morning.
2 weeks ago, she underwent Right hip replacement. She finished a course of prophylactic heparin injections 4 days ago
US Doppler shows acute DVT extending from her popliteal vein into her femoral vein covering the entire thigh
CT Chest by PE protocol shows PE in the RLL with signs of early infarction.
![Page 15: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/15.jpg)
Venous Thromboembolism (VTE) Incidence and Impact in the United States
Approximately 2 million VTEs occur every year1
Each year 1 person in 1,000 will experience his/her first VTE in the US2
One third manifest pulmonary embolism ([PE], with or without deep vein thrombosis [DVT])
Death within 1 month of diagnosis2: ~6% of DVT cases ~12% of PE cases
Recurrent DVT: ~17% of DVT patients 2 years after initial
treatment*3
~30% of DVT patients 8 to 10 years after initial treatment*†3,4
1. Hirsh J, Hoak J. Circulation. 1996;93:2212-2245. 2. American Heart Association. Heart Disease and Stroke Statistics – 2004 Update. 3. Prandoni P et al. Haematologica. 1997;82:423-428. 4. Pengo V et al. N Engl J Med. 2004;350:2257-2264.
*High dose standard heparin or LMWH for at least 10 days; oral anticoagulant therapy was initiated during the first week and continued for at least 3 months; †Unfractionated heparin was given as an initial IV bolus followed by IV infusion; oral anticoagulant therapy was initiated after the first week and continued for at least 6 months.
![Page 16: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/16.jpg)
NBC News Correspondent David Bloom. While covering thewar in Iraq, Bloom was stricken with a fatal pulmonary embolism (PE), acomplication of DVT.
“ March 2, 2011 Serena Williams suffers pulmonary embolism Tennis star undergoes emergency treatment in L.A. for complications stemming from blood clot in lungs”
![Page 17: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/17.jpg)
Venous thrombosis-Clinical Manifestations
1. Extremities, Deep venous thrombosis (DVT)
Swelling, Redness/dusky color, warmth
sudden onset vs. gradual
2. Pulmonary embolism (PE)
SOB, acute versus gradual
Diminished exercise capacity
chest pain syncope cardiac
arrest/deathLess common sites: Portal vein, renal vein,cerebral sinus vein
![Page 18: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/18.jpg)
PE: Clinical Presentation
Symptom or Sign Percent
Dyspnea 82
Respiratory Rate >20/min 60
Heart Rate >100 beats/min 40
Chest pain 49
Cough 20
Syncope 14
Hemoptysis 7Goldhaber SZ, et al. Lancet 1999.
Most Common Sx/Si Among 2454 Pts in International Cooperative Pulmonary Embolism Registry
Goldhaber SZ, et al. Lancet 1999.
![Page 19: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/19.jpg)
Venous thrombosis-Limb Sudden or gradual
occlusion of a vein leads to -impaired venous return
with blood flow “backing up”, edema develops due to increased hydrostatic pressure, pain present
-blood flow through alternative routes leads to dilated superficial veins
-thrombus leads to inflammatory response with redness and warmth of the affected area
![Page 20: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/20.jpg)
Venous thrombosis-Pulmonary embolism
Part of the thrombus can break off and travel through major veins, right heart into pulmonary artery until it becomes lodged
Blood flow through pulmonary artery is impaired by thrombus, Lung tissue past thrombus cannot participate in gas exchange, tissue can infarct (Pulmonary infarct)
Increased pulmonary vascular resistance can lead to right ventricular dysfunction
Increased airway resistance d/t bronchoconstriction
Decreased pulmonary compliance If clot burden is high ( saddle embolus-both PA
affected): cardiovascular arrest and death
![Page 21: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/21.jpg)
ALTERED VESSELS ~inflammatory damage ~mechanical injury ~hypoxia
VENOUS STASIS ~immobility ~paralysis ~reduced flow states
ALTERED COAGULABILITY ~inflammatory stimuli ~consumption of endogenous anticoagulants
Virchow’s Triad
![Page 22: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/22.jpg)
Risk Factors for Venous Thrombosis
Common: Trauma Post-surgery Immobility/Inactivity Obesity Pregnancy Estrogens/Birth control Malignancy Age Previous history of DVT/PE
![Page 23: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/23.jpg)
Age and VENOUS THROMBOSIS
AGE
RIS
K O
F T
HR
OM
BO
SIS
1:100,000
1:1000
1:100
40 y.o. 75 y.o.
1:10,000
![Page 24: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/24.jpg)
Risk Factors for Venous Thrombosis
Inherited procoagulant disorders
-Factor V Leiden-Prothrombin gene
mutation-Protein C deficiency-Protein S deficiency-Antithrombin deficiency
Acquired hypercoagulable states
-clotting factors ( increased factors VII, VIII, XI)
-systemic disorders( PNH, Myeloproliferative disorders, Malignancy, Vasculitic/proinflammatory disorders, Antiphospholipid syndrome)
-Disseminated intravascular coagulation ( DIC)
-Heparin-induced thrombocytopenia and thrombosis syndrome
![Page 25: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/25.jpg)
Diagnosis of venous thrombosis
Symptoms
Blood work -elevated D-Dimer-Negative D-Dimer rules out thrombosis
Imaging for Limb: -Compression ultrasonography +/-US-Doppler,
Imaging for Lungs:-CT scan-VQ scan
![Page 26: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/26.jpg)
Hypercoagulable States
Defect Incidence in Population
Percent of Patients with Procoagulant
States
Factor V Leiden 5-10% 20-60%
Prothrombin Gene Mutation 2-4% 6-8%
Homocysteinemia -- 10%
Protein C Deficiency 1:200 <5%
Protein S Deficiency -- <5%
Antithrombin Deficiency 1:2-5,000 <1%
Dysfibrinogenemia Not known ~1-2%
Known Malignancy 16-18%
![Page 27: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/27.jpg)
Treatment of acute DVT/PE
Treatment for acute clot is heparin Heparin inactivates activated clotting
factors (clotting cascade initiated) Minimum time: 5 days and until warfarin
is fully therapeutic -overlap heparin with therapeutic INR x 2 days Warfarin used to prevent additional clots Warfarin does not treat the acute clot-do
not give alone for acute event! Reduction of vitamin K dependent factors
takes at least 4-5 days regardless of INR
![Page 28: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/28.jpg)
If we cannot anticoagulate
Does not address the underlying hypercoagulable statePreference for removable devices, great for short term protection of patient (bleeding, surgery etc)Long-term: increases the risk of DVT
![Page 29: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/29.jpg)
Bates, S. M. et al. N Engl J Med 2004;351:268-277
![Page 30: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/30.jpg)
Objectives
1. Arterial Thrombosis: -Pathophysiology, Risk factors,
Symptoms and Signs, treatment 2. Venous Thrombosis:-Pathophysiology, Risk Factors,
Symptoms and Signs 3. Common anticoagulants 4. Hereditary and acquired
Hypercoagulable Disorders
![Page 31: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/31.jpg)
Anticoagulants
Unfractionated Heparin
LMWH-enoxaparin ( Lovenox)-Dalteparin (Fragmin) Direct Xa inhibitor-Fonaparinux ( Arixtra) Vitamin K
antagonist-Warfarin (Coumadin)
New oral anticoagulants
Direct thrombin inhibitor
Dabigatran ( Pradaxa) Anti-Xa inhibitors-Rivaroxaban ( Xarelto)-Apixaban (Eliquis)
![Page 32: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/32.jpg)
The Heparin Family
N-acetylglucosamine 6-O-sulfate
Glucuronic acid
N-sulfated glucosamine3,6-O-disulfate
Iduronic acid2-O-sulfate
N-sulfatedglucosamine6-O-sulfate
UFH LMWH PENTASACCHARIDE (Fondaparinux)
![Page 33: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/33.jpg)
![Page 34: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/34.jpg)
Mechanism of Action - UFH
UFH
5-sugarsequence
Factor Xa
Factor IIa
Factor Xai
Factor IIai
Antithrombin
![Page 35: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/35.jpg)
Mechanism of Action - LMWH
LMWH
5-sugarsequence Factor Xa
Antithrombin Factor Xai
![Page 36: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/36.jpg)
Warfarin
Interferes with carboxylation of vitamin K dependent factors
Factor II (thrombin), VII, IX, X,
protein C, protein S Prothrombin Time (PT)/INR is used
to monitor warfarin because half life of Factor VII is the shortest (5-7 hours)
![Page 37: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/37.jpg)
Warfarin
Synthesis of Non
Functional Coagulation
Factors
Also affects Protein C
and protein S
Antagonismof
Vitamin K
Warfarin Mechanism of Action
Vitamin K
VII
IX
X
II
![Page 38: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/38.jpg)
0
20
40
60
80
100
0 1 2 3 4 5 6
Days
Fac
tor
acti
vity
(%
)Factor VII Factor IX Factor X Factor II
Effect of Warfarin on Factor Activity
Therapeutic INR once ALL factors suppressed
![Page 39: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/39.jpg)
Mechanisms of Anticoagulation1
1. Adapted with permission from Petitou M et al. Nature. 1991;350(suppl):30-33; http://www.nature.com/2. Hirsh J, Fuster V. Circulation. 1994;89:1449-1468.3. Hirsh J et al. Chest. 2001;119(1 suppl):64S-94S.4. Nutescu EA, et al. Pharmacotherapy. 2004;24(7 Pt 2):82S-87S. 5. Weitz JI, Hirsh J. Chest. 2001;119(1 suppl):95S-107S.
XIIa
IIa
Xa
Intrinsic system(surface contact)
XII
XI XIa
Tissue factor
IX IXa VIIa VII
VIII VIIIa
Extrinsic system(tissue damage)
X Xa
V Va
II
Fibrinogen Fibrin
(Thrombin)IIaFactor Xa inhibitors4,5
Direct thrombin inhibitors4,5
Vitamin K antagonists4
Heparins2,3
![Page 40: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/40.jpg)
INR – Oral (warfarin) anticoagulation
Therapeutic Range INR 2.0-3.0
(Most situations) Mechanical Heart Valve INR
2.5-3.5
Dose:Diet (Vitamin K)MetabolismConcurrent medications
**The higher the INR the higher the bleeding risk
![Page 41: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/41.jpg)
Drug Interactions
![Page 42: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/42.jpg)
Management of excessive anticoagulation
Depends on INR level and presence of bleeding symptoms
Options: Hold warfarin dose until INR is in therapeutic
range Give Vitamin K (po, im, iv), if patient not
bleeding-takes 24-48 hours Give FFP iv (contains all clotting factors), results
in partial or total reversal-used before urgent/emergent procedures-used for severe or life threatening bleeding-works immediately Recombinant Factor VII if all else fails ( caution:
thrombogenic!)
![Page 43: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/43.jpg)
Antithrombotic Characteristics
Drug Half-LifeDuration of
effectRenal
clearance?Reversal
UFH(sq BID-TID) 1-2 hrs 8-12 hrs No Protamine
LMWH(sq q day-BID) 4-7 hrs 12-24 hrs
Yes(>30 ml/min)
±Protamine (40-70%)
Warfarin(po daily) 20-60 hrs 48-72 hrs No
FFPVitamin K
Fondaparinux(sq daily) 17-21 hrs 24 hrs
Yes(>30 ml/min)
None(VIIa conc?)
Dabigatran12-17 hrs 24-36 hrs
Yes(>30 ml/min)
None(Dialysis)
Rivaroxaban
5-9 hrs 24 hrs yes None
![Page 44: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/44.jpg)
New anticoagulants-No monitoring
Dabigatran (Pradaxa): oral direct thrombin inhibitor
FDA approved in US for Atrial fibrillation, 150 mg po bid
slightly less bleeding risk than warfarin
Rivaroxaban (Xarelto): oral Factor Xa inhibitor
FDA approved for A fib ( 20 mg qd) and DVT/PE treatment, 15 mg bid x 3 weeks, then 20 mg qd
Apixaban (Eliquis): oral Factor Xa inhibitor 5 mg po bid for non-valcular A fib Increased risk of stroke after stopping drug
(Rebound)
![Page 45: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/45.jpg)
Bridging case
45 y/o female PMH:
HTN ‘idiopathic’ DVT in 2005, PE in 2/2008-
20 days after leg injury. Antiphospholipid-Antibody syndrome
(APLS)=severe hypercoagulable disorder
Chronic warfarin therapy (since 2/08) without complications
![Page 46: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/46.jpg)
Oh by the way…
Scheduled for FME in 7 days and was instructed to stop warfarin tomorrow.
![Page 47: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/47.jpg)
Bridging
Use of parenteral anticoagulants during period of withholding warfarin therapy e.g. colonoscopy, surgery, multiple
dental extraction Parenteral anticoagulants: heparin, low
molecular weight heparin (LMWH), Minimize period of time without
anticoagulation
![Page 48: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/48.jpg)
Typical bridging protocol
5 days before procedure-stop warfarin (pm dose)
3 days before procedure start LMWH ( am injection)
No LMWH on morning of procedure Restart LMWH within 24-48 hrs after
procedure Start warfarin on the evening of
procedure: remember that is takes several days before warfarin is at therapeutic levels
Follow INR and stop LWMH once INR is at target
Anticoagulation clinics/PCP
![Page 49: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/49.jpg)
What’s this patient’s risk of having thrombotic event off
anticoagulation?a. Low
b. Moderate
c. High
![Page 50: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/50.jpg)
Managing patients on anticoagulation requiring
invasive procedures Low risk: no recent (>12 months) venous
thromboembolism, atrial fibrillation without h/o stroke or other risk factors or bileaflet mechanical cardiac valve in aortic position
PLAN: - stop warfarin 4-5 days before surgery, allow
INR to return to normal. Use postoperative prophylaxis and simultaneously begin warfarin
![Page 51: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/51.jpg)
Intermediate risk of thromboembolism
Mechanical Heart Valve Bileaflet (St. Jude) aortic valve and one:
A.fib, prior CVA/TIA, DM, HTN, HF, age >75 Atrial Fibrillation
CHADS-2 score of 3 or 4 VTE within past 3 to 12 mo
Non-severe thrombophilia (i.e. heterozygous Factor V Leiden)
PLAN: Stop warfarin 4-5 days before surgery, allow INR to return
to normal, cover the patient beginning 2 d preoperatively with low dose UFH or prophylactic dose LMWH and then start therapy with LMWH and warfarin postoperatively vs. higher dose UFH or full dose LMWH
CHADS-2: CHF, HTN, age >75, DM, prior TIA/CVA
![Page 52: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/52.jpg)
Managing patients on anticoagulation requiring invasive
procedures High risk: recent (<3 months) history of
venous thromboembolism, Severe thrombophilia (APLAS, protein C or S def, multiple), mechanical cardiac valve in mitral position and old model of cardiac valve (Ball/cage), Atrial Fibrillation with CHADS-2 score of 5 or 6. Recent (3 mo) CVA/TIA, Rheumatic valve disease
PLAN: -stop warfarin 4-5 days before surgery, allow INR
to return to normal -begin therapy with FULL dose of UFH or LMWH
as the INR falls ( about 2 days preop) -UFH as sc. Injection, then IV drip in hospital -dc drip about 5 hrs before surgery -stop LMWH 12-24 hrs before surgery
![Page 53: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/53.jpg)
Managing patients on anticoagulation requiring invasive
procedures-alternative option Low risk of bleeding Continue warfarin at lower dose and operate at an INR of
1.3-1.5 Intensity has been shown in RCT to be safe in gynecologic
and orthopedic surgery patients Dose of warfarin can be lowered 4-5 days preop Warfarin therapy can be restarted at regular doses
postoperatively, supplemented with low dose UFH or prophylactic LMWWH
![Page 54: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/54.jpg)
Anticoagulants for Bridging
Therapeutic dose (DVT/PE treatment dose) enoxaparin (Lovenox)1 mg/kg SQ bid or
1.5 mg/kg/day dalteparin (Fragmin)200 IU/kg/day or 100
IU/kg/bid Unfractionated heparin with therapeutic
APTT (61-84 sec) Low dose
enoxaparin 30 mg SQ twice daily or 40 mg SQ once daily
dalteparin 2500 or 5000 units SQ once daily
![Page 55: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/55.jpg)
Bridging Plan - LMWH Stop warfarin approximately 5 days prior to
procedure (Grade 1B) Initiate LMWH once INR below therapeutic level
Usually day 4 or 3 prior Last dose of LMWH 24 hr before surgery (grade
1C) Administer approximately ½ total daily dose
instead of 100% (grade 1C) Resume LMWH approximately 24 hours after
procedure when there is adequate hemostasis (grade 1C)
Resume warfarin approximately 12 – 24 hrs after surgery (grade 1C)
![Page 56: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/56.jpg)
Oral Anticoagulation and Dental Surgery
“Although there is a theoretical risk of hemorrhage after dental surgery, the risk is minimal, and the risk may be greatly outweighed by the risk of thromboembolism.”1
Grade 1B recommendation: continue warfarin around time of minor dental procedure (single or multiple tooth extraction and root canal procedure)2
1. Arch Intern Med 1998;158:1610-6 2. Chest 2008;133:299S
![Page 57: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/57.jpg)
Objectives
1. Arterial Thrombosis: -Pathophysiology, Risk factors,
Symptoms and Signs, treatment 2. Venous Thrombosis:-Pathophysiology, Risk Factors,
Symptoms and Signs 3. Common anticoagulants 4. Hereditary and acquired
hypercoagulable Disorders
![Page 58: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/58.jpg)
Indications of a congenital Defect in a patient with
thrombosis First thrombosis age <50 Family history of thrombosis Recurrent episodes of thrombosis Thrombosis at unusual sites Neonatal thrombosis Thrombosis without apparent
antecedent thrombogenic event
![Page 59: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/59.jpg)
What are the (known) inherited Hypercoagulable
States? 1. Factor V Leiden-Factor Va becomes resistant to activated Protein C (APC resistance)
2. Prothrombin gene mutation (Factor II)
Mildly elevated plasma levels of Factor II
3. Deficiencies of Antithrombin III (AT III), Protein S and Protein C
-Reduced amounts of natural anticoagulants leads to imbalance in the clotting cascade
![Page 60: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/60.jpg)
How common are these disorders?
![Page 61: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/61.jpg)
Case #2 19 y/o healthy and
active woman is evaluated for swollen RLE x 5 days in local ER
Started on birth control 5 mo prior
US shows Right popliteal DVT
“Hypercoag panel” drawn at time of presentation:
Heterozygous for Factor V Leiden
Issues: Long-term
management Pregnancy Surgeries Genetic counseling
(siblings, children)
![Page 62: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/62.jpg)
Factor V Leiden
Autosomal dominant genetic mutation (1994 in the Dutch city of Leiden)
This is not a deficiency! but a structural change in the Factor V
Diagnosis by DNA analysis ( heterozygotes vs homozygotes)
![Page 63: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/63.jpg)
Mechanism of Factor V Leiden
1. Increased coagulation:-Factor V Leiden is inactivated more slowly
by activated protein C than normal factor V
-More Factor Va is available within the coagulation cascade, thereby leading to more thrombin generation
2. Decreased anticoagulation: -Normal factor V, cleaved at position 506, is
a cofactor together with protein S for protein C. Protein C cleaves factor VIIIa and factor Va
-Lack of normally cleaved Factor V decreases the anticoagulant property of protein C (APC resistance)
![Page 64: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/64.jpg)
Factor V Leiden Mechanism
TF+ VIIa
IX+VIII
X+V (=abnormal)
II
Fibrinolysis CLOT
Antithrombin
Protein C and
Protein S
Degradation of Factors V, VIII
![Page 65: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/65.jpg)
![Page 66: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/66.jpg)
Prothrombin gene mutation
PG20120A (Factor II mutation) genetic polymorphism that causes
increased amount of prothrombin (factor II) in the circulation
occurs in ~2-3% of Caucasian population in the U.S.
associated with VENOUS thrombosis at least half of clotting events
precipitated by some stimulus most people with the mutation DON’T
clot
![Page 67: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/67.jpg)
Testing for prothrombin gene mutation
DNA analysis for prothrombin G20210A mutation Distinguishes heterozygotes and
homozygotes
![Page 68: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/68.jpg)
What is the risk of thrombosis?
![Page 69: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/69.jpg)
Deficiencies of natural anticoagulants
Leads to imbalance between coagulation and anticoagulation
Natural anticoagulants: Protein C,S and Antithrombin deficiency
Patients present early in life, usually with venous thrombosis
Often additional risk factors are present
![Page 70: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/70.jpg)
Natural Anticoagulants: AT III, protein C, S
TFPI TF+ VIIa
IX+VIII
X+V
II
Fibrinolysis CLOT
Antithrombin
Protein C and
Protein S
Heparin
Degradation of Factors V, VIII
Protein C/S deficiency
![Page 71: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/71.jpg)
Asymptomatic carriers Thrombosis is a multi-risk disorder Additional risk factors are often required
to cross the thrombosis threshold Some carriers will never have a
thrombotic event Asymptomatic family members rarely
need anticoagulation Prophylaxis during high risk events:
pregnancy, surgery or immobilization Estrogen therapy ( OCP, perimenopausal)
is contraindicated-use anticoagulation
![Page 72: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/72.jpg)
Acquired hypercoagulable States
Malignancy Presence of a central venous catheter Surgery, especially orthopedic Trauma Pregnancy Oral contraceptives Hormone replacement therapy or Tamoxifen, Anti-angiogenesis (Bevacizumab,
Thalidomide,Lenalidomide) Congestive heart failure
Antiphospholipid antibody syndrome Myeloproliferative disorders (Polycythemia vera, Essential
thrombocythemia) Paroxysmal nocturnal hemoglobinuria (PNH) Inflammatory bowel disease Nephrotic syndrome Hyperviscosity (Waldenstrom's macroglobulinemia,
Multiple myeloma) Marked leukocytosis in acute leukemia Sickle cell anemia HIV/AIDS
![Page 73: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/73.jpg)
Antiphospholipid Antibody Syndrome
Acquired hypercoagulable state Presence of antibodies that cause
clotting (anticardiolipin AB, Lupus anticoagulant, beta2-glycoprotein1-AB) plus clinical event ( arterial or venous thrombosis)
Very high risk of recurrence after initial event (10%/year, cumulative)
Life-long anticoagulation recommended
Need to “bridge” before procedures
![Page 74: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/74.jpg)
Case #3 40 y/o female presents with idiopathic DVT
LLE/PE at the age of 35 Treatment with heparin/ warfarin x 6 months Does well until 2 years later when she presents
with recurrent PE, anticoagulation restarted 7 months later she has a 3rd PE while therapeutic
on warfarin (INR at 2.5), Filter placed, O2 dependent
Hypercoagulable panel shows very high titers for Antiphospholipid antibodies
Goal INR is raised to 3-4 6 months later, she develops DVT in RLE while
on warfarin, gets transitioned to twice daily LMWH injections
![Page 75: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/75.jpg)
Cancer is a hypercoagulable state
5-10% of patients presenting with idiopathic VTE will be diagnosed with cancer in the next 12-24 months 1
VTE has been found in 20-50% of cancer patients at autopsy 2
Cancer patients have higher rates of recurrent VTE and bleeding than patients without cancer3,4,5
Cancer patients with VTE have higher mortality than those without VTE 6
1 J Thromb and Haemost 2004;2: 885 2 Am J Med Sciences 1938; 34: 566 3 JCO 2000;18: 3078 4 Medicine 1999;78: 285 5 Blood 2002; 100: 3484 6 NEJM 2000; 343: 1846
![Page 76: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/76.jpg)
Thrombosis and Cancer
DVT/PE most common Any location possible Recommendation: preferred is
LMWH sc daily/bid as long as cancer not in remission due to high risk of recurrence
Alternative: warfarin
Need bridging if on warfarin.
![Page 77: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/77.jpg)
Questions??
![Page 78: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/78.jpg)
Dental case studies
Assistant Professor of MedicineHematology/Oncology
![Page 79: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/79.jpg)
Case 8
A 66 y/o male with atrial fibrillation and no prior stroke, otherwise healthy, comes in for dental extraction. You should
A) stop coumadin 4-5 days beforeB) lower his dose for 4-5 days to achieve an
INR of 1.3-1.5 and proceed with extraction
C) Bridge the patient with LMWH after he stops coumadin 4-5 days before
D) Bridge the patient with UFH after he stops coumadin 4-5 days before
![Page 80: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/80.jpg)
Case 9
A 55 y/o male with h/o unprovoked PE 2 months prior comes in for elective dental work (implants). How should you manage his anticoagulation?
A) Proceed with dental implants and stop coumadin 5 days before and for 7 days post-op.
B) Bridge the patient before , then hold anticoagulation post-op for 1 week
C) Postpone implantsD) Stop Coumadin, place temporary filter
and proceed with implants. Have his PCP restart anticoagulation.
![Page 81: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/81.jpg)
Case 1075 y/o patient undergoes dental extraction. He is
on chronic coumadin for atrial fibrillation and restarts after his extraction. 1 week after extraction, he calls you with c/o fever and facial swelling. He reports pus from the socket. You see him in the office and diagnose him with a post-procedural infection. On exam, he is hypotensive and tachycardic, you decide to admit him to the hospital. He is found to be bacteremic and started on iv antibiotics with cefotetan. On the 3rd hospital day , the patient becomes somnolent and later unconscious. A CT scan of his head most likely will show
A) a new stroke B) intracranial hemorrhageC) a malignancyD) encephalitis
![Page 82: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/82.jpg)
Case 11
45-year-old white male embedded as a reporter with the army division that was invading Iraq during 2003, with no previous medical problems, took a break and died. On autopsy, pulmonary embolism was found.
Name risk factors for Pulmonary embolism in this case that may have been present.
![Page 83: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/83.jpg)
Case 12
28 year-old white female who has just given birth 3 weeks previously without complication, develops sudden difficulty breathing while sitting in your treatment chair. Describe your approach to the patient regarding differential diagnosis, acute management and diagnostic strategies.
![Page 84: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/84.jpg)
Case 13 50-year-old alcoholic man, with known
liver cirrhosis and an h/o of esophageal bleeding due to esophageal varies presents for dental work. He has just been diagnosed with head and neck cancer and needs radiation. After evaluation, you determine he needs FME. Complete blood count shows WBC 7500/uL, Hgb 7.5 gm/dL, Hct 22.5%, platelet count 90,000/uL. INR 1.9, aPTT 50 sec.
Which parts of the hemostastic system are impaired?
Which options do you have to safely perform a FME? Which agents can you use to reverse his “auto-anticoagulation”.
![Page 85: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/85.jpg)
Case 14 A 52 y/o man is evaluated because of a warm,
swollen leg and a history of trauma to the leg 2 weeks ago while on a ski trip in Europe. The leg first became painful on the plane ride home. The patient has mild hypertension that is treated with metoprolol but has no other medical problems. He is not taking any other medications. He is a nonsmoker. There is no family history of thromboembolic disease.
What do you think is going on with the patient? What is the next diagnostic step?
![Page 86: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/86.jpg)
Case 15
Heparin affects which pathway?A) IntrinsicB) Extrinsic
![Page 87: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/87.jpg)
Case 16
The aPTT is used to monitor anticoagulation with unfractionated heparin. Warfarin is monitored by INR.
A) TrueB) False
![Page 88: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/88.jpg)
Case 17
Explain, how warfarin works, which factors are affected and the reason for individual dosing.
![Page 89: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/89.jpg)
Case 18
A 38 y/o man is receiving warfarin therapy for DVT of the left leg that he developed 3 weeks ago. He comes in for his scheduled INR check. He denies any gingival bleeding, hematuria, nosebleeds, or gastrointestinal disorder but reports a sore throat and fever that started about 1 week ago. He has not been able to swallow and has consequently been on a mostly liquid diet for the last week.
![Page 90: Introduction to thrombosis Christiane.Thienelt@ucdenver.edu Assistant Professor of Medicine Hematology/Oncology2014.](https://reader038.fdocuments.us/reader038/viewer/2022102814/551c53205503467b488b5377/html5/thumbnails/90.jpg)
Case 18 cont.
On PE: temp 38 C ( 100.4F). His posterior pharynx is erythematous but without exudates. Cardiopulmonary examination is normal. There is 1+ edema of the left leg with tenderness in the popliteal fossa ( improved since 2 weeks ago) and several scattered ecchymoses on the forearms and legs.
Labs: Hgb 15, Hct 41% leucocytes 10 K, Platelets 240 INR 6.0 aPTT 37 (normal up to 29)
Why is the INR so high?What is the best course of action?